NASDAQ:PLSE Pulse Biosciences Q3 2026 Earnings Report $48.32 -1.43 (-2.87%) As of 02:11 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pulse Biosciences EPS ResultsActual EPSN/AConsensus EPS -$0.35Beat/MissN/AOne Year Ago EPSN/APulse Biosciences Revenue ResultsActual RevenueN/AExpected Revenue$0.60 millionBeat/MissN/AYoY Revenue GrowthN/APulse Biosciences Announcement DetailsQuarterQ3 2026Date11/4/2026TimeBefore Market OpensConference Call DateWednesday, November 4, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Pulse Biosciences Earnings HeadlinesPulse Biosciences, Inc (NASDAQ:PLSE) Stock Has Average Target Price of $50.20October 6 at 6:15 AM | americanbankingnews.comPulse Biosciences (PLSE) Stock Fair Value Rises After Analysts Back NsPFA DataOctober 3, 2026 | finance.yahoo.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 7 at 1:00 AM | Banyan Hill Publishing (Ad)Pulse Biosciences: Promising Technology, But Hard To Justify Its ValuationSeptember 27, 2026 | seekingalpha.comPulse Biosciences (NASDAQ:PLSE) Research Coverage Started at BTIG ResearchSeptember 26, 2026 | americanbankingnews.comPulse Biosciences Completes Enrollment in 100-Patient Thyroid Nodule StudySeptember 16, 2026 | finance.yahoo.comSee More Pulse Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pulse Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulse Biosciences and other key companies, straight to your email. Email Address About Pulse BiosciencesPulse Biosciences (NASDAQ:PLSE). is a medical technology company developing bioelectric therapies based on its proprietary Nano-Pulse Stimulation (NPS) technology. The platform delivers short, nonthermal electrical pulses that temporarily affect cell membranes and are designed to selectively target unwanted cells while preserving surrounding tissue. The company’s lead commercial product is the CellFX System, a dermatology platform designed to treat certain benign skin lesions and other dermatologic conditions using NPS technology. Pulse Biosciences is also advancing applications in areas including cardiac surgery, cardiac ablation and oncology, although several of these programs remain investigational and subject to regulatory review. Founded in 2009 and headquartered in Hayward, California, Pulse Biosciences serves the medical technology and healthcare markets primarily through its development of physician-focused systems and disposable treatment accessories. The company is led by President and Chief Executive Officer Burke T. Barrett. Its products and development programs are directed toward clinicians and healthcare providers in the United States and other international markets where applicable regulatory clearances have been obtained.View Pulse Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Wall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the StakesInvenTrust’s Sell-Off Opens a Potential Entry PointCuraleaf’s Higher Aurora Bid Raises the Stakes in Cannabis Consolidation Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
